Iijima Hiroko, Kudo Masatoshi, Kubo Shoji, Kurosaki Masayuki, Sakamoto Michiie, Shiina Shuichiro, Tateishi Ryosuke, Osamu Nakashima, Fukumoto Takumi, Matsuyama Yutaka, Murakami Takamichi, Takahashi Arata, Miyata Hiroaki, Kokudo Norihiro
Follow-up Survey Committee, Japan Liver Cancer Association, Osaka, Japan.
Department of Internal Medicine, Division of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
Hepatol Res. 2023 Oct;53(10):895-959. doi: 10.1111/hepr.13953. Epub 2023 Sep 5.
For the 23rd Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 20 889 newly registered patients and 42 274 previously registered follow-up patients were compiled from 516 institutions over a 2-year period from January 1, 2014 to December 31, 2015. Basic statistics compiled for patients newly registered in the 23rd survey were cause of death, past medical history, clinical diagnosis, imaging diagnosis, treatment-related factors, pathological diagnosis, recurrence status, and autopsy findings. Compared with the previous 22nd survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, had more female patients, had more patients with non-B non-C HCC, had smaller tumor diameter, and was more frequently treated with hepatectomy. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma (combined HCC and intrahepatic cholangiocarcinoma) by treatment type and background characteristics for patients newly registered between 2004 and 2015 whose final outcome was survival or death. The median overall survival and cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter, Child-Pugh grade, or albumin-bilirubin grade) and by treatment type (hepatectomy, radiofrequency ablation therapy, transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy, and systemic therapy). The same values were also calculated according to registration date by dividing patients newly registered between 1978 and 2015 into five time period groups. The data obtained from this nationwide follow-up survey are expected to contribute to advancing clinical research and treatment of primary liver cancer in the world.
在日本进行的第23次全国原发性肝癌随访调查中，从2014年1月1日至2015年12月31日的两年时间里，收集了来自516家机构的20889例新登记患者和42274例既往登记的随访患者的数据。第23次调查中新登记患者的基本统计数据包括死亡原因、既往病史、临床诊断、影像诊断、治疗相关因素、病理诊断、复发情况和尸检结果。与之前的第22次调查相比，肝细胞癌（HCC）患者在临床诊断时年龄更大，女性患者更多，非B非C型HCC患者更多，肿瘤直径更小，接受肝切除术治疗的频率更高。对2004年至2015年间新登记的最终结局为生存或死亡的HCC、肝内胆管癌和肝内胆管癌合并肝细胞癌（HCC合并肝内胆管癌）患者，按治疗类型和背景特征计算累积生存率。通过将患者按背景因素组合（肿瘤数量、肿瘤直径、Child-Pugh分级或白蛋白-胆红素分级）和治疗类型（肝切除术、射频消融治疗、经动脉化疗栓塞、肝动脉灌注化疗和全身治疗）进行划分，计算HCC的中位总生存期和累积生存率。还根据登记日期，将1978年至2015年间新登记的患者分为五个时间段组，计算相同的值。预计从这次全国随访调查中获得的数据将有助于推动全球原发性肝癌的临床研究和治疗。
